M蛋白联合C反应蛋白在多发性骨髓瘤中的临床价值

Clinical value of M protein and C-reactive protein in multiple myeloma

目的探讨M蛋白联合C反应蛋白在多发性骨髓瘤中的临床价值。方法选取2014年1月至2020年12月本院收治的86例多发性骨髓瘤患者作为研究对象,随机分为两组,每组43例。对照组给予硼替佐米联合沙利度胺及地塞米松方案治疗,观察组给予硼替佐米联合来那度胺及地塞米松方案治疗。比较两组临床疗效、不良反应发生情况、无病生存率及M蛋白下降>50%、C反应蛋白(CRP)下降>50%占比情况。结果观察组治疗总有效率为93.02%,明显高于对照组的76.74%,差异有统计学意义(P<0.05)。观察组不良反应发生率为13.95%,明显低于对照组39.53%,差异有统计学意义(P<0.05)。治疗后,治疗有效患者M蛋白水平下降>50%、CRP水平下降>50%占比均明显高于治疗前(P<0.05),治疗无效患者治疗前后M蛋白下降>50%、CRP水平下降>50%占比比较差异无统计学意义。结论硼替佐米联合来那度胺及地塞米松方案治疗多发性骨髓瘤效果显著,且不良反应较少,可明显降低患者M蛋白及CRP水平,可为临床评估患者疾病严重程度及预后提供有效依据,值得临床推广应用。

Objective To investigate the clinical value of M protein combined with C-reactive protein in multiple myeloma.Methods 86 patients with multiple myeloma who were admitted to our hospital from January 2014 to December 2020 were selected as the research subjects and they were randomly divided into two groups,with 43 cases in each group.The control group was given bortezomib combined with thalidomide and dexamethasone regimen,and the observation group was given bortezomib combined with lenalidomide and dexamethasone regimen.The clinical efficacy,incidence of adverse reactions,disease-free survival rate,and the proportion of M protein decreased>50%and C-reactive protein(CRP)decreased>50%were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.02%,which was significantly higher than 76.74%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 13.95%,which was significantly lower than 39.53%in the control group,and the difference was statistically significant(P<0.05).After treatment,the proportion of M level protein decreased by>50%and CRP level decreased>50%in the effective patients were significantly higher than those before treatment(P<0.05).The proportion of M protein decreased>50%and CRP level decreased>50%in the ineffective patients before and after treatment,the difference was not statistically significant.Conclusion Bortezomib in combination with lenalidomide and dexamethasone regimen is effective in the treatment of multiple myeloma,and has fewer adverse reactions,and significantly reduces the levels of M protein and CRP in patients.